167 results about "Intestinal microorganisms" patented technology

The invention belongs to the technical field of biological medicine, and relates to application of a clerodendranthus spicatus tea bag in regulating intestinal excretion and reducing uric acid. One of the purposes of the invention is to provide the application of the clerodendranthus spicatus teabag in regulating intestinal tracts to reduce uric acid According to a preferred embodiment, the clerodendranthus spicatus teabag regulates ATP binding cassette transporter G2 and inhibits uricase activity. The invention provides the application of the clerodendranthus spicatus teabag in regulating the intestinal microbial environment and reducing uric acid, and the clerodendranthus spicatus teabag has remarkable beneficial effects. The clerodendranthus spicatus teabag can effectively regulate the structure and the function of intestinal microflora, especially the enrichment amount of characteristic bacteria Muriaculum in the intestinal tract, further strengthens the probiotic activity of the intestinal flora, and is helpful for maintaining the steady state of uric acid in the body. The multi-way synergistic effect not only provides an innovative strategy for preventing and treating hyperuricemia and related metabolic diseases, but also avoids side effects possibly brought by traditional medicines, and shows good application prospects and clinical values.

The invention relates to the technical field of bioinformatics and medical artificial intelligence data processing, in particular to a colorectal cancer risk assessment system based on intestinal microbiological diversity, which comprises a multi-modal time sequence data acquisition module, a multi-modal time sequence data acquisition module, a target object microbiome time sequence feature data acquisition module and a target object microbiome time sequence feature data acquisition module, obtaining current medical resource load state parameters; the compliance entropy calculation module is used for resolving longitudinal compliance entropy representing the data uploading continuity willingness of the target object; the artifact interference identification module is used for generating a physiological disturbance probability value and a denoised pathological evolution feature vector; the double-constraint risk assessment module is used for calculating an initial pathological risk index of the target object; the dynamic decision scheduling module is used for determining a final dynamic intervention strategy for the target object; according to the method, the false positive and false alarm rate is remarkably reduced, and the technical pain point that real pathological evolution and environmental interference are difficult to distinguish by a traditional method is solved.

The invention relates to the technical field of medical assistance, in particular to a depression risk assessment method and system based on intestinal flora characteristics. The method comprises the following steps: acquiring an individual enteric microorganism sample, performing nucleic acid sequencing on the enteric microorganism sample, and determining abundance data of functional genes related to a neural activity metabolic pathway in enteric microorganisms; carrying out metabolite detection on the intestinal microorganism sample, and determining concentration data of metabolites related to the neural activity metabolic pathway in the intestinal microorganisms; based on the abundance data of the functional genes and the concentration data of the metabolites, data fusion processing is carried out, a neural activity metabolism function spectrum is constructed, and the neural activity metabolism function spectrum is a multi-dimensional feature vector; and inputting the neural activity metabolic function spectrum into a pre-trained risk assessment model, and outputting a depression risk score of the individual. The accuracy and repeatability of evaluation are remarkably improved, and the method has great potential for early screening, dynamic monitoring and personalized health management.

The utility model discloses an automatic microorganism enrichment and adsorption device and relates to the technical field of biomedicine. The device comprises an enrichment adsorption box, the enrichment adsorption box is provided with a harmful bacterium adsorption assembly used for removing harmful bacteria in intestinal microorganism mixed liquid, a beneficial bacterium enrichment assembly used for enriching beneficial bacteria in the microorganism mixed liquid, a beneficial bacterium dissociation assembly used for dissociating the beneficial bacteria and antibody magnetic beads which are coupled together, and a beneficial bacterium collection bottle used for collecting the beneficial bacteria. And the negative pressure assembly is used for enabling the intestinal microorganism mixed liquid to flow through the harmful bacterium adsorption assembly, the beneficial bacterium enrichment assembly and the beneficial bacterium dissociation assembly and enter the beneficial bacterium collection bottle. According to the utility model, specific intestinal microorganisms can be selectively screened, so that a solid foundation is laid for precise transplantation of intestinal flora and precise treatment of specific related diseases of the intestinal tract.

The invention relates to nutritional compositions for infants and in particular formulae for infants comprising human milk oligosaccharides, specific bifidobacteria, and urea as non-protein nitrogen source for improving the intestinal microbiota.

The invention provides a risk prediction method and device based on digestive system department diseases, and the method comprises the steps: obtaining clinical data and intestinal microbiome data of a target object, and carrying out the preprocessing and standardization of a clinical data set and the intestinal microbiome data; inputting the preprocessed clinical data into a first encoder to obtain a clinical feature matrix; inputting the preprocessed intestinal microbiome into a second encoder to obtain an intestinal microbiome characteristic matrix; based on a cross-modal attention mechanism, performing bidirectional attention calculation on the clinical feature matrix and the intestinal microbiome feature matrix to obtain fusion features; the method comprises the following steps: performing two-way interaction and fusion on clinical data and microbiome data of a target object, calculating an SHAP value of a fusion feature, taking the fusion feature as an input of a preset risk prediction module, and obtaining a risk prediction value of a disease of the digestive system department, and obtaining the risk prediction value of the disease of the digestive system department through two-way interaction and fusion of the clinical data and the microbiome data of the target object. The method can assist doctors in interpreting which key clinical indexes or intestinal microorganism characteristics have relatively large multi-risk prediction influence, assist clinical decision, and further improve the interpretability of digestive system department disease risk prediction.

The disclosure relates to anti-inflammatory, oxygen-scavenging membrane vesicles derived from bacteria with modified or absent lipopolysaccharide. The disclosure further relates to pharmaceutical and nutritional compositions comprising these vesicles, and methods of using the same. Methods include therapeutic treatment of diseases associated with gut oxygenation and inflammation, such as inflammatory bowel disease, as well as non-therapeutic methods for supporting gastrointestinal health, promoting a healthy inflammatory response, and maintaining a balanced gut microbiota.

Methods for improving the gut microbiota of a subject, increasing one or more bacterial communities belonging to the Helicobacterium or Euglobulaceae families in their colonic flora, for the prevention, treatment, or relief of disease, and for increasing the level of short-chain fatty acids in the colon, comprising administering to the subject a composition containing allulose, erythritol, or a combination thereof. The composition used in the above methods comprises allulose, erythritol, or a combination thereof. The composition comprises allulose, erythritol, or a combination thereof, and one or more colonic bacterial communities from the Helicobacterium or Euglobulaceae families.

A kind of microplastic toxicity exposure risk evaluation method for fish with wild grass carp as sample, the present application relates to the field of microplastic toxicity exposure risk evaluation, specifically relates to a kind of microplastic toxicity exposure risk evaluation method for fish with wild grass carp as sample.The present application is to solve the problem that the existing evaluation method is single, cannot comprehensively and accurately evaluate the toxicity exposure risk of microplastic to fish.Method: I, set experimental group;II, input wild grass carp to experimental group, record body length and weight;III, feed cultivation, respectively add corresponding microplastic particles, the control group does not add microplastic particles;IV, combine the weight change of wild grass carp, body length change, feeding rate, mortality and intestinal microbial diversity index for calculation;The higher the value of comprehensive index R, the higher the toxicity risk of microplastic to fish is evaluated.The present application is used to evaluate the toxicity exposure risk of microplastic to fish with wild grass carp as sample.

The invention relates to the technical field of active polysaccharides, in particular to an arrowroot active polysaccharide as well as a preparation method and application thereof. In an infrared spectrum of the arrowroot active polysaccharide, the arrowroot active polysaccharide at least has characteristic absorption peaks at the following positions: 3317 cm, 2911 cm, 1404 cm <-1 >, 1021 cm <-1 > and 642 cm. The polysaccharide is extracted and separated from yam beans, and the polysaccharide has a protective effect in a mouse model with hepatic fibrosis induced by ligation of bile ducts, also has a regulating effect on intestinal microbiota, and exerts anti-fibrosis activity.

The invention discloses application of copper sulfate in inhibition of trichomonad activity, in-vitro tests prove that copper sulfate can induce oxidative stress of trichomonad, interfere with sulfur-containing amino acid metabolism, destroy the structure of trichomonad cells and reduce the active oxygen content and hydrogenase membrane potential of trichomonad bodies, and the minimum inhibition concentration of copper sulfate on trichomonad within 48 hours is 640 micrograms / mL. In-vivo tests prove that copper sulfate is added into drinking water according to the concentration of 500 mu g / mL, and is periodically fed once every 15 days and continuously 4 days each time, so that the number of trichomonad in the oral cavities of laying pigeons of silver-feather king pigeons and young pigeons of white-feather king pigeons can be remarkably reduced, and meanwhile, the quality of pigeon eggs is improved, and the immunity and intestinal microbial flora are improved; the application method provided by the invention is safe, efficient and low in cost, the addition concentration of copper sulfate is easy to control, no drug residue risk exists, and the composition can replace traditional antibiotics such as metronidazole to be used for preventing and treating trichomonad of pigeons, is suitable for a large-scale meat pigeon breeding scene and has a wide application prospect.

This invention discloses an antimicrobial peptide cAMP-1 derived from the intestinal microorganisms of wild rodents and its applications, belonging to the field of biotechnology. The amino acid sequence of the antimicrobial peptide cAMP-1 is shown in SEQ ID NO:1. The antimicrobial peptide cAMP-1 exhibits highly efficient, rapid, and safe antimicrobial activity against Streptococcus suis type II. It significantly inhibits bacterial growth even at low concentrations, with a minimum inhibitory concentration (MIC) of 16 µg / mL. Time-kinetic kinetics results show that the antimicrobial peptide can kill all Streptococcus suis type II within 30 min and 15 min at concentrations of 2×MIC and 4×MIC, respectively. Furthermore, within several times the effective concentration range, the peptide exhibits almost no hemolytic activity and low cytotoxicity within a safe dosage range, demonstrating its promising application as a novel anti-infective candidate drug.

A technique for calculating a risk of mild cognitive impairment for a subject who submitted a stool sample and a questionnaire, and a system for calculating a risk indicator for mild cognitive impairment is presented. The system includes an extraction unit configured to extract, from a first data related to intestinal microbiota data of a user, a second data related to a factor or intestinal microorganisms that is indicated to relate to the mild cognitive impairment; and a calculation unit configured to input the second data into a model for calculating a probability of the user having the mild cognitive impairment, the model having a third data as a variable, the third data being related to one or more intestinal microorganisms that represents a difference between intestinal microbiota of healthy participants and intestinal microbiota of patients with the mild cognitive impairment, and to calculate the risk of the user for the mild cognitive impairment, wherein the risk for the mild cognitive impairment is a probability of developing or having already developed the mild cognitive impairment.

The invention discloses a construction method of an animal model for depression caused by night illumination, and belongs to the technical field of animal model construction. Comprising the following steps: (1) selecting 8-week male C57BL / 6J mice as experimental animals, and dividing the experimental animals into a modeling group and a control group; (2) the modeling group simulates staying up late at night, and (3) animal behavioral depression experiments are respectively performed on the modeling group and the control group mice, and compared with the control group mice, the modeling group mice show typical depression behaviors, so that the animal model of depression caused by night illumination is obtained. The method has the beneficial effects that the animal model for the depression caused by the night illumination is successfully established by utilizing a controllable light night exposure experiment, the intestinal flora analysis is performed on excrement of a modeling group and a control group, and the change of the intestinal microbial flora induced by the abnormal night illumination is analyzed; a theoretical basis is provided for developing a rhythm intervention strategy of targeted intestinal microorganisms, and early prevention and precise treatment of depression are assisted.

The invention provides a nervous and mental health risk assessment and grading system based on intestinal microorganisms, and belongs to the technical field of nervous and mental health risk assessment. The invention provides a nervous and mental health risk assessment system. The nervous and mental health risk assessment system comprises a data acquisition and processing module, a microbial species abundance analysis module, a model calculation module and a nervous and mental health risk assessment result output module, the invention further provides a nervous and mental health risk grading system, and a risk grading module is added on the basis of the nervous and mental health risk evaluation system. According to the method, the multi-dimensional microbiome data is integrated and analyzed, the microbiological abundance data is converted into objective, quantifiable and graded output neurological and mental health results, early recognition of high-risk individuals and targeted intervention are facilitated, a reliable basis is provided for clinical decision making, and the method has good universality and expandability.

The invention discloses a cinnamyl aldehyde modified montmorillonite nanosheet capable of inhibiting bacterial quorum sensing as well as a preparation method and application of the cinnamyl aldehyde modified montmorillonite nanosheet. According to the modified nanosheet, a two-dimensional montmorillonite nanosheet is taken as a carrier, and cinnamyl aldehyde is intercalated into an interlayer region of the two-dimensional montmorillonite nanosheet. The modified montmorillonite nanosheet can achieve the effect of inhibiting inflammation by inhibiting bacterial quorum sensing and adjusting the abundance of intestinal microorganisms, effectively relieves symptoms induced by IBD, has good stability, biocompatibility and biodegradability, and can be used for treating inflammatory bowel diseases.

This invention provides the application of Lycium barbarum polysaccharide (LBP) in the preparation of drugs for the prevention or treatment of intestinal flora and metabolic disorders. Research results show that LBP can significantly improve cisplatin-induced intestinal microbiota and metabolic disorders in rats, manifested by a significant reduction in CDDP-induced serum AST and ALT levels, and improvement in the degree of liver tissue lesions. Furthermore, LBP did not exhibit toxicity in rats. LBP enhanced the diversity and richness of the gut microbiota, restored the structure of dominant symbiotic bacteria, inhibited the proliferation of potentially pathogenic bacteria, and promoted the enrichment of functional bacteria related to SCFAs generation. LBP also restored abnormal metabolism in branched-chain amino acid and aromatic amino acid metabolism, one-carbon metabolism, and lipid metabolism. This invention provides a theoretical basis for the application of natural active polysaccharides in the prevention and treatment of intestinal microbiota and metabolic disorders.

The invention discloses a method for analyzing tryptophan metabolites of intestinal microorganisms, which comprises the following steps: sample pretreatment, on-machine detection and data processing, and can be used for quantitatively analyzing 11 indole derivatives (IAA, IPA, ILA, IArA, IAM, IPYA, IAld, TRM, IET, ICA and IS) in a serum or excrement sample. According to the method, through comprehensive methodology verification, on the basis of keeping high sensitivity and accuracy, one-time analysis can be completed only in 6 minutes on a machine, and the detection efficiency is high; the TRP microbial metabolite indole metabolite detection kit can be used for detecting TRP microbial metabolite indole metabolite, covering 11 types of indole metabolites in serum and excrement samples, covering IAld, IET, IArA and other key indole derivatives related to intestinal flora, realizing relatively comprehensive detection of TRP microbial metabolite indole metabolites, and providing a new tool for revealing a complex mutual relationship between intestinal microorganisms and host health.

This invention relates to a targeted ileal delivery method for endotoxin chelating agents, their preparation, and applications, belonging to the technical field of pharmaceutical formulations. The drug comprises a specific polymer copolymer containing a three-dimensional framework of organic carbon-carbon chemical bonds and amino groups. The aim is to deliver the polymer chelating agent to the distal small intestine for release, thereby chelating pathogen-associated molecular patterns produced by intestinal microorganisms, including endotoxins and CpG-DNA. The complex formed by the polymer chelating agent and pathogen molecular patterns released in the ileum can be excreted from the digestive tract, thereby reducing inflammation and alleviating various metabolic diseases.

This invention discloses the application of inosine in the preparation of drugs that promote testosterone secretion, belonging to the field of biomedical technology. The effective active ingredient of the above-mentioned drugs is only inosine or its pharmaceutically acceptable salts. The dosage forms of the above-mentioned drugs are tablets, capsules, oral liquids, lozenges, granules, powders, pills, powders, ointments, elixirs, suspensions, powders, or injections. The routes of administration of the above-mentioned drugs are oral, transdermal, intramuscular, subcutaneous, or intravenous injection. Since inosine exists under physiological conditions and can be metabolized by intestinal microorganisms, reasonable supplementation of inosine is a safer and more effective method for restoring testosterone. Inosine helps maintain the homeostasis of the intestinal flora, and the experimental results of this invention further show that inosine can restore the damaged intestinal barrier, thus making it safer. Moreover, this invention does not directly supplement exogenous testosterone, therefore it is less likely to induce spermatogenesis disorders or promote prostatic hyperplasia.

The invention provides polygonatum kingianum hepta-oligosaccharide and application thereof.Fermented polygonatum kingianum is prepared through fermentation of pediococcus ethanolidurans, fermented polygonatum kingianum polysaccharide is extracted from the fermented polygonatum kingianum, and the brand-new polygonatum kingianum hepta-oligosaccharide is obtained through extraction and purification, and the structural formula of the polygonatum kingianum hepta-oligosaccharide is alpha-D-Glcp-1-(2-beta-D-Fruf-1) 5-2-beta-D-Fruf. The probiotic can be selectively utilized by intestinal microbiota at cecum and colon parts, the relative abundance of beneficial intestinal microbiota is specifically increased, the proliferation of enterococcus and lactobacillus is remarkably promoted, the pH value of colon can be reduced, the intestinal microecological balance is optimized, the biosynthesis of short-chain fatty acid is stimulated, and the probiotic has an excellent prebiotic effect and a wide application prospect.

The objective is to provide a method for predicting or determining animal diseases, a method for calculating insurance premiums, and an animal disease prediction system. The method for determining or predicting the health status of an animal, characterized by comprising the step of determining the health status of an animal or predicting its future health status using information on whether or not the intestinal microbiota of an animal other than a human contains predetermined bacteria such as Streptococcus constellatus, Streptococcus anginosus, and Slackia exigua.

The invention provides a construction method of engineered lactic acid bacteria for constitutive expression of SodA protein and application of the engineered lactic acid bacteria in treatment of IBD. The invention provides a construction method of engineered lactic acid bacteria (KI (at) lSodA) for relieving IBD (Infectious Bronchitis Disease) constitutive expression SodA protein. A verification experiment result shows that the KI (at) lSodA highly expresses the SodA protein, and the oxidative stress management capability of the strain is improved; meanwhile, the KI (at) lSodA also has long-term use safety, the treatment of the KI (at) lSodA remarkably relieves the colitis symptoms and in-vivo inflammation conditions of mice in an acute stage, a recovery stage and a chronic state, and the KI (at) lSodA shows a strong intestinal microbial diversity recovery capability in all three experimental models, and particularly shows a remarkable repair effect in a recovery stage model. Therefore, the invention provides a new basis for IBD treatment.

The invention discloses application of a ginsenoside and panoxadiol composition in preparation of a preparation for improving intestinal microbiota, and relates to the technical field of plant extract application, the composition at least comprises ginsenoside Rb3 and 20 (S)-protopanoxadiol which are used after being mixed according to the mass ratio of 1: (1-2); the composition can reverse damaged intestinal flora of high-fat diet mice, ginsenoside Rb3 and 20 (S)-protopanoxadiol are combined for application, the lipid metabolism related gene expression level is adjusted through the synergistic effect, the intestinal microbial flora composition of the high-fat diet mice can be effectively recovered, and an experimental basis is provided for research of an intestinal liver axis mechanism.

The invention relates to the technical field of medicine, and particularly discloses a liver cirrhosis specific intestinal flora marker composition and application of the liver cirrhosis specific intestinal flora marker composition in noninvasive diagnosis. The intestinal microbial flora is selected from the group consisting of clostridium, Bacteroides, Thalictrum, Wehonor genus, Streptococcus genus, Klebsiella genus, and Prevotella genus; according to the method, a non-invasive solution is provided for screening and diagnosis of liver cirrhosis by detecting a synergistic change mode of specific florae such as clostridium, bacteroides, thickenella, prevotella, Wehonor, streptococcus and klebsiella in an excrement sample; the limitation that traditional liver needle biopsy is invasive and imaging examination is insensitive to early-stage lesions is avoided.

This invention discloses the application of a composition in the preparation of foods or medicines that reduce blood lead levels, belonging to the field of food or pharmaceutical applications. The composition is for improving intestinal microecology, comprising inulin, galactooligosaccharides, polydextrose, and water-insoluble dietary fiber, wherein the weight ratio of inulin, galactooligosaccharides, polydextrose, and water-insoluble dietary fiber is 25:25:20:30, and the composition is taken immediately after being dissolved in warm water before meals. This invention, through the rational combination of water-insoluble dietary fiber and functional polysaccharides, adjusts the release rate of nutrients in the intestine, slows down digestion, absorbs and eliminates toxic substances from food, reduces intestinal permeability, and simultaneously possesses the functions of water absorption and swelling, gradient adhesion, mechanical isolation, mesh adsorption, ion exchange, and microbial regulation, providing a favorable environment and food for the growth of intestinal microorganisms, and effectively reducing blood endotoxins and blood lead levels, enhancing immunity, and preventing chronic diseases.

This application discloses a method, apparatus, device, and medium for processing data related to neuropsychiatric diseases, relating to the field of data processing technology. The method includes: acquiring gut microbial species characteristic data of a target sample, including relative abundance characteristics or species presence / absence status characteristics; acquiring the target disease and its corresponding decision tree binary classification model, which is trained using the CatBoost algorithm, and the model's output categories include a target category and a null category; inputting the gut microbial species characteristic data into the model, and outputting a probability value indicating that the target sample belongs to the target category; and generating a data processing result corresponding to the target sample based on the probability value. Using the neuropsychiatric disease data processing method of this application can improve the accuracy and cross-disease generalization ability of neuropsychiatric disease data processing models.

The present application relates to the field of poultry feeding, and provides a method for improving the production performance and intestinal flora stability of chicks. According to the present application, the part of microorganisms on the eggshell will enter the digestive system through the process of pecking the shell before the chicks hatch, thereby affecting the intestinal microorganisms. By spraying probiotics after the eggs are placed on the tray, and without using antibiotics in the subsequent feeding and management process after the chicks are hatched, the growth rate of the chicks is improved, the stability of the intestinal flora of the chicks is enhanced, the health of the chicks is beneficial, and the "antibiotic-free breeding" is beneficial to be realized. The present application is simple in operation and obvious in effect, and provides a new idea for reducing the use of antibiotics and realizing antibiotic-free breeding.

The application discloses a combination of intestinal microbial functional markers for diagnosing allergic risk of infants and young children and a construction method and application of a model thereof. The combination of intestinal microbial functional markers for diagnosing allergic risk of infants and young children and the kit thereof can accurately and efficiently diagnose the microecological allergic risk of infants and young children of different ages. By integrating multi-dimensional characteristics such as functional gene abundance and KEGG metabolic pathway function activity level, the model can reveal the core mechanism of affecting the host immunity from the perspective of the function of the flora, thereby improving the prediction efficiency and enhancing the biological interpretability of the model. The AUC of the method reaches 0.84 on the test set, indicating that the method has good ability to distinguish allergic and non-allergic individuals. The models of different age groups all have high consistency, proving that the method is stable and reliable and can meet the accuracy requirements of clinical auxiliary decision-making.

The application discloses an intestinal microbial marker combination for cirrhosis diagnosis and application thereof, which is composed of 8 specific intestinal bacterial species. The application accurately identifies the core combination from 181 differential characteristics by performing metagenomic sequencing on fecal samples of cirrhosis patients and healthy controls, and combining random forest, LASSO regression and recursive feature elimination algorithms. The random forest diagnosis model based on the 8 markers realizes an excellent performance of area under curve (AUC) 0.841, sensitivity 84.3% and specificity 83.7% on a completely independent test set, and the performance does not decrease compared with the full feature model in the case of reducing the number of characteristics by 86.9%. The marker combination provided by the application is highly simplified and has strong discrimination, and provides a clear and efficient microbiological basis and technical scheme for developing a cirrhosis non-invasive diagnosis kit, a gene chip and other products based on intestinal flora.